The lead product candidate is ELX-02, a small-molecule drug designed to restore production of full-length functional proteins, currently in Phase 2 clinical development for treatment of Alport syndrome in patients with nonsense mutations. Eloxx has exclusively licensed ZKN-013 to Almirall, S.A., who is developing it for rare skin diseases.
Cyborg Score Rationale
Eloxx is in a strong pre-commercial position with recent Nasdaq uplisting (June 2026), meaningful clinical progress on lead candidate ELX-02 in Phase 2 trials for rare kidney diseases, and strategic partnerships including exclusive licensing with Almirall. The company operates in high-unmet-need rare disease markets with potential for premium pricing upon approval, though clinical and regulatory risks remain material.
Top Insights
Recent Nasdaq uplisting (June 9, 2026) with stock up ~230% since IPO, signaling strong market interest in rare disease genetic therapies
Lead candidate ELX-02 in Phase 2 trials for Alport syndrome and other nonsense mutation kidney diseases with significant unmet medical needs
Strategic partnership with Almirall for ZKN-013 in rare skin diseases reduces development risk on secondary program
Proprietary TURBO-ZM™ technology platform and ERSG chemistry enable targeted treatment of premature stop codon diseases with potential multi-indication upside
Named Competitors
Translarna — Nonsense suppression therapy for rare genetic disorders
Other ERSG candidates — Competing modulation and genetic therapy approaches
Recent Developments
(June 2026) Nasdaq uplisting with trading commencing June 9, 2026, following IPO on May 29, 2026
(July 2024) First healthy volunteers dosed in Phase 1 trial for ZKN-013; positive FDA pre-IND meeting for ELX-02 in Alport syndrome
(June 2026) Stock price gained approximately 230% since public offering
Open the full interactive Eloxx Pharmaceuticals, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.